SERA实时信号 | 通过Getagraph.com最大化利润

购买 109393 min ago

@ $8.36

发出时间: 13 Feb 2024 @ 22:31

回报率: 27.56%

上一信号: Feb 12 - 22:31

上一信号: 出售

回报率: -4.40 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 21:43):

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes...

Stats
今日成交量	7 012.00
平均成交量	212 664
市值	347.49M
EPS	$0 ( 2024-03-27 )
下一个收益日期	( $-0.230 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.20
ATR14	$0.0520 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Boniface John J.	Buy	48 909	Class A Common Stock
2024-03-28	Boniface John J.	Buy	24 474	Class A Common Stock
2024-03-27	Boniface John J.	Sell	48 909	Class A Common Stock
2024-03-28	Boniface John J.	Sell	24 474	Class A Common Stock
2024-03-27	Boniface John J.	Sell	48 909	Stock Option (right to buy)

INSIDER POWER
56.94
Last 97 transactions
Buy: 4 223 994 \| Sell: 1 702 853

音量相关性

長: -0.04 (neutral)

短: -0.22 (neutral)

Signal:(45.676) Neutral

Sera Prognostics, Inc. 相关性

10 最正相关
BLPH	0.96
SVFC	0.957
MKGI	0.945
AZRX	0.933
MOTNU	0.929
BCYP	0.928
MLTX	0.91
PESI	0.91
HUGE	0.908
DSEY	0.907

10 最负相关
ZNTE	-0.953
FNCB	-0.947
ATHN	-0.938
CARA	-0.933
BSRR	-0.932
BCOW	-0.931
BRKL	-0.929
BLFY	-0.928
FFIC	-0.927
FRST	-0.927

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Sera Prognostics, Inc. 相关性 - 货币/商品

-0.25
( neutral )

0.45
( neutral )

0.00
( neutral )

0.01
( neutral )

-0.85
( strong negative )

0.24
( neutral )

Sera Prognostics, Inc. 财务报表

Annual	2023
营收:	$306 000
毛利润:	$-804 000 (-262.75 %)
EPS:	$-1.160

FY	2023
营收:	$306 000
毛利润:	$-804 000 (-262.75 %)
EPS:	$-1.160

FY	2022
营收:	$268 000
毛利润:	$75 000.00 (27.99 %)
EPS:	$-1.430

FY	2021
营收:	$82 000.00
毛利润:	$45 000.00 (54.88 %)
EPS:	$-2.04

Financial Reports:

No articles found.

Sera Prognostics, Inc.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.